Cel-Sci Corp(CVM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 8 at 8:45 AM ET (Korea 10/8 21:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.58 | Insider Own | 6.94% | Shs Outstand | 17.6M | Perf Week | -6.7% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | 69.39% | Shs Float | 16.4M | Perf Month | 26.62% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 11.77% | Short Float | 3.78% | Perf Quarter | 41.3% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | 9.82% | Short Ratio | 2.54 | Perf Half Y | -54.44% |
| Sales | 0.00B | P/B | 3.13 | EPS next 5Y | 25.29% | ROA | -108.91% | Short Interest | 0.62M | Perf YTD | -62.93% |
| Book/sh | 0.62 | P/C | 5.25 | EPS past 3/5Y | 37.9% 23.99% | ROE | -252.53% | 52W High | -81.63% ($10.62) | Perf Year | -80.56% |
| Cash/sh | 0.37 | P/FCF | - | Sales past 3/5Y | - | ROIC | -140.57% | 52W Low | 119.1% ($0.89) | Perf 3Y | -94.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.69% | Gross Margin | - | Volatility(W/M) | 21.16% 9.9% | Perf 5Y | -99.36% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | -99.08% |
| Dividend Ex-Date | - | Quick Ratio | 1.42 | EPS Q/Q | 65.72% | Profit Margin | - | RSI (14) | 52.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.48 | Sales Q/Q | - | SMA20 | 6.12% ($1.84) | Beta | 0.59 | Target Price | $12.5 |
| Payout | - | Debt/Eq | 0.72 | Earnings | 2026/8/17 | SMA50 | 18.57% ($1.64) | Rel Volume | 1.58 | Prev Close | $2.13 |
| Employees | - | LT Debt/Eq | 0.47 | EPS/Sales Surpr. | - | SMA200 | -30.43% ($2.8) | Avg Volume(3M) | 0.24M | Price | $1.95 |
| IPO | 1983/12/8 | Option/Short | No/Yes | Trades | 1124 | Volume | 385,241 | Change | -8.45% |
🧬 This is a U.S. clinical-stage biotech company developing Multikine, an immunotherapy designed to improve treatment outcomes for head and neck cancer patients through pre-surgical (neoadjuvant) immunotherapy.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded more than usual That is 158% of its average volume.
CVM has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.3% this year.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.4%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #445 of 592 in the industry
Based on market cap of $34M.
FAQ
What kind of company is CVM?
CVM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CVM?
The market cap of CVM is approximately $34M, ranking 5,084 within its sector.
What is the 52-week high and low for CVM?
CVM has recorded a 52-week high of $10.62 and a low of $0.89.
